发布: 2025年06月20日第15卷第12期 DOI: 10.21769/BioProtoc.5349 浏览次数: 934
评审: Alessandro DidonnaSérgio RibeiroAnonymous reviewer(s)
Abstract
Endometritis is a prevalent gynecological condition, often resulting from bacterial infections, which poses significant risks to women’s reproductive health, including recurrent pregnancy loss, spontaneous abortion, and intrauterine adhesions. While conventional in vitro models have provided valuable insights into the pathogenesis of bacterial-induced endometritis, they often fail to replicate the complex cellular architecture and microenvironment of the endometrium due to species-specific differences and variations in the menstrual cycle. In this study, we present a novel organoid-based culture system that establishes a bacterial-induced endometritis model using endometrial organoids derived from primary epithelial cells. This protocol involves culturing endometrial organoids in a Matrigel-based three-dimensional matrix, followed by infection with Escherichia coli at a defined multiplicity of infection (MOI). The model effectively recapitulates key pathological features of bacterial-induced endometritis, including disruption of the epithelial barrier, release of inflammatory cytokines, and cellular damage. By preserving epithelial polarity, this approach offers enhanced physiological relevance, improves host–pathogen interaction studies, and provides a robust platform for evaluating potential therapeutic interventions.
Key features
• Establishes apical-out endometrial organoids to model pathogen-induced endometritis via natural infection routes.
• Utilizes primary human endometrial epithelial cells to preserve cellular diversity and mimic the native endometrial microenvironment.
• Provides a versatile platform for investigating host–pathogen interactions and evaluating potential therapeutic interventions in bacterial-induced endometritis.
• Developed apical-out endometrial organoids to better mimic tissue structure and enhance pathogen infection for host–pathogen interaction studies.
Keywords: Endometrial organoid (子宫内膜类器官)Background
Endometritis is a bacterial infection that leads to the disruption of the endometrial epithelial barrier, causing a range of adverse effects. With the growth of assisted reproductive technologies, gaining a better understanding of endometritis has become increasingly important, especially in developing models that assess how pathogenic bacteria impact the endometrial barrier and its receptivity [1–2]. In vitro models have become essential for exploring the mechanisms underlying endometritis and the interactions between the host and pathogens [3]. Cell-based systems provide a controlled environment that closely replicates human endometrial cells and physiological conditions [4]. These models allow for the examination of immune responses, pathogen evasion strategies, and the role of virulence factors in disease progression [5]. Additionally, in vitro platforms are crucial for evaluating the effectiveness and toxicity of therapeutic compounds in the early stages of drug development, reducing the dependency on expensive animal models. However, despite the growing interest in advanced culture systems for studying endometrial infections, there is still a lack of comprehensive reviews on these methodologies.
Research on endometrial models has evolved from the use of in vitro cell lines to animal models. In vitro 2D culture systems limit essential cell–cell interactions required to replicate the in vivo microenvironment [6–8]. Additionally, the use of non-human primates in research poses challenges, including high costs, specialized resources, and ethical concerns. Significant anatomical and physiological differences between human and mouse reproductive systems necessitate careful consideration of interspecies variations in research [9]. Recent advancements in the development of self-organizing three-dimensional organoids have addressed these limitations [10–11]. Following enzymatic digestion, endometrial tissue forms hollow, spherical organoids in specialized media, preserving genetic integrity during cell division and differentiation. These organoids can also recover secretory functions post-cryopreservation [12–13]. Furthermore, the epithelial cells of endometrial organoids (EOs) show positive responses to estrogen and progesterone, opening new avenues for research into endometrial-related disorders [5,14]. Traditional 2D endometrial cell cultures have limited lifespans and rapidly lose their phenotypic and hormonal responsiveness. In contrast, organoids preserve these characteristics and demonstrate remarkable expansion potential, overcoming the senescence typically observed in primary cell cultures [15–16]. Endometrial organoids hold promise for uncovering key intracellular signaling pathways and providing insights into the overall morphological features of tissues, thus offering a deeper understanding of human endometrial physiology and pathology at the cellular level [17–18]. When endometrial organoids are cultured in Matrigel, their apical surface faces inward, mimicking the native structure of the endometrium. In this polarized state, the epithelial barrier function is likely intact, with tight cell junctions and minimal antigen exposure, resulting in lower susceptibility to pathogen infection. However, when Matrigel is removed and the organoids are transferred to low-adhesion plates, the polarity is reversed, and the epithelial surface is exposed outward. This change increases the likelihood of pathogen interaction, as the exposed cell surface may facilitate pathogen attachment. The outward-facing polarity may also lead to looser cell junctions or expose specific receptors, further promoting pathogen adhesion and infection.
In endometritis, pathogens first encounter the surface of the endometrial epithelium before initiating infection. The organoids we have constructed resemble the deeper glandular structures of the endometrium, where the epithelial surface is located at the center of the glands. In humans, under the influence of hormones, these glands gradually move upward and extend, eventually forming the endometrial epithelium, with the epithelial surface becoming exposed. Therefore, we reverse the polarity of the organoids to replicate this process, ensuring that the epithelial surface is on the exterior, which is critical for subsequent experimental procedures, such as pathogen infection studies. This polarity reversal allows for a more accurate simulation of how pathogens interact with the surface epithelium during infection, improving the relevance and reliability of our model. Our novel endometrial organoid infection model addresses these limitations by optimizing bacterial exposure parameters, enhancing infection consistency, and maintaining organoid viability. This improved model closely mimics the in vivo endometrial microenvironment, providing a robust platform for investigating host–pathogen interactions, inflammatory responses, and potential therapeutic interventions. Additionally, this protocol may be adapted for studying other bacterial pathogens or exploring the impact of various environmental factors on endometrial health.
Materials and reagents
Biological materials
1. 0.5 × 1.0 cm human endometrial tissue (generated in patients undergoing hysteroscopic surgery)
2. Escherichia coli (ATCC-25922)
Reagents
1. Collagenase II (Sigma, catalog number: C2-28-100MG)
2. Collagenase IV (Sigma, catalog number: C4-28-100MG)
3. Y-27632 (MCE, catalog number: H9. Y-10071/CS-0131)
4. Matrigel (Corning, catalog number: 356255)
5. DMEM/F12 (HyClone, catalog number: SH30272.01)
6. B27 (Gibco, catalog number: 17504-044)
7. N2 supplement (Gibco, catalog number: 17502-048)
8. A83-01 (MCE, catalog number: HY-10432)
9. EGF (MCE, catalog number: HY-P7109)
10. Rspondin-1 (MCE, catalog number: HY-P7114)
11. Noggin (MCE, catalog number: HY-P7051A)
12. Dimethyl sulfoxide (DMSO) (Sigma, catalog number: D2650)
13. TrypLE Express (Gibco, catalog number: 12604-013)
14. Cell recovery solution (Corning, catalog number: 354270)
15. Antibiotic-antifungal (MCE, catalog number: HY-K1058)
16. LB broth (Solarbio, catalog number: L8291)
17. Fetal bovine serum (FBS) (Gibco, catalog number: A5669710)
18. Cryopreservation solution (Gibco, catalog number: 12648010)
19. PBS (Gibco, catalog number: 10010001)
20. Advanced DMEM/F-12 (Gibco, catalog number: 12634028)
21. Estradiol (MCE, catalog number: HY-B0141)
22. Progesterone (MCE, catalog number: HY-N0437)
Solutions
1. Endometrial organoid culture medium (see Recipes)
2. Collagenase type IV (2× and 1× solutions) (see Recipes)
3. Collagenase type II (2× and 1× solutions) (see Recipes)
Recipes
1. Endometrial organoid culture medium
First, prepare the growth factor stock solutions. Dissolve 50 μg of EGF powder in 500 μL of ddH2O to obtain a 100 μg/mL EGF solution. Aliquot 100 μL per tube and store at -20 °C for up to 3 months. Further dilute 50 μL of the 100 μg/mL EGF solution with 450 μL of ddH2O to achieve a final concentration of 10 μg/mL, and store under the same conditions. Similarly, dissolve 50 μg of Noggin powder in 500 μL of ddH2O to obtain a 100 μg/mL Noggin solution and store at -20 °C for up to 3 months. Dissolve 50 μg of R-spondin-1 powder in 500 μL of ddH2O to prepare a 100 μg/mL R-spondin-1 solution and store at -20 °C for up to 3 months. For small-molecule inhibitors, dissolve 5 mg of A83-01 powder in 2.5 mL of DMSO to obtain a 2 mg/mL (4.7 mM) A83-01 stock solution and store at -20 °C for up to 3 months. Similarly, dissolve 5 mg of Y-27632 powder in 1 mL of DMSO to prepare a 5 mg/mL (20 mM) Y-27632 stock solution and store at -20 °C for up to 3 months. Next, prepare the endometrial organoid culture medium by adding 400 μL of B27, 200 μL of N2, 100 μL of EGF (10 μg/mL), 20 μL of Noggin (100 μg/mL), 20 μL of R-spondin-1 (100 μg/mL), 2.1 μL of A83-01 (4.7 mM), and 10 μL of Y-27632 (20 mM) into 19.2 mL of DMEM/F12. Mix thoroughly with a pipette and store at 4 °C until use (maximum 3 days).
Reagent | Final concentration | Quantity or Volume |
---|---|---|
DMEM/F12 | - | 19.2 mL |
B27 (50×) | 1× | 400 μL |
N2 (100×) | 1× | 200 μL |
EGF (10 μg/mL) | 50 ng/mL | 100 μL |
Noggin (100 μg/mL) | 100 ng/mL | 20 μL |
Rspondin-1 (100 μg/mL) | 100 ng/mL | 20 μL |
A83-01 (4.7 mM) | 0.5 μM | 2.1 μL |
Y-27632 (20 mM) | 10 μM | 10 μL |
2. Collagenase type IV
Dilute 0.02 g of collagenase type IV powder in 10 mL of PBS and sterilize the solution by passing it through a 0.22 μm filter. 2× aliquots can be stored at -20 °C for ≤ 6 months. Bring collagenase type IV (1×) to room temperature before use.
Reagent | Final concentration | Quantity or Volume |
---|---|---|
Collagenase type IV | 2 mg/mL | 0.02 g |
PBS | 1× | 10 mL |
Total (optional) | 2 mg/mL | 10 mL |
3. Collagenase type II
Dilute 0.02 g of collagenase type II powder in 10 mL of PBS and filter sterilize. 2× aliquots can be stored at -20 °C for ≤ 6 months. Bring collagenase type II (1×) to room temperature before use.
Reagent | Final concentration | Quantity or Volume |
---|---|---|
Collagenase type II | 2 mg/mL | 0.02 g |
PBS | 1× | 10 mL |
Total (optional) | 2 mg/mL | 10 mL |
Laboratory supplies
1. 15 mL conical tubes (Thermo, catalog number: 339659)
2. 50 mL conical tubes (Thermo, catalog number: 0644320)
3. 10 μL pipette tips (Thermo, catalog number: 9400303)
4. 300 μL pipette tips (Thermo, catalog number: 9401253)
5. 1,000 μL pipette tips (Thermo, catalog number: 9401115)
6. Nunclon multi dish 24 wells (Thermo, catalog number: 142475)
7. Nunc EasYDish 100 mm (Thermo, catalog number: 150466)
8. Ultra-low attachment plates (Corning, catalog number: 3473)
9. Cryogenic vials (Corning, catalog number: CLS430488)
10. Agar plates (Corning, catalog number: 1.46231)
11. Filters (Corning, catalog number: CLS431220)
12. Cryovials (BRAND, catalog number: Z334081)
13. Pipettes (Thermo, catalog number: 4651080N)
14. Pipette tips (Thermo, catalog number: 9401113)
Equipment
1. Refrigerator (2–8 °C)
2. Freezer (-20 °C, -80 °C)
3. Water bath (37 °C) (KUANSON, model: J-HH-2A)
4. NordicSafe® Class II biological safety cabinet (ESCO, model: NC2-L)
5. Laboratory centrifuge with rotors for 15 and 50 mL conical tubes (Thermo, catalog number: 75009740)
6. HeracellTM VIOS 160i CO2 incubator (Thermo, catalog number: 51033547)
7. Forceps (Thermo, catalog number: DS0399-0002)
8. Cell counter (MARIENFELD, catalog number: AP-0650010)
9. Microscope (OLYMPUS, catalog number: IX53)
10. Bacterial incubator (Thermo, catalog number: 360)
11. Spectrophotometer (Thermo, catalog number: 840-297000)
12. Cell shaker (Thermo, catalog number: 889501D)
Procedure
文章信息
稿件历史记录
提交日期: Mar 18, 2025
接收日期: May 13, 2025
在线发布日期: Jun 5, 2025
出版日期: Jun 20, 2025
版权信息
© 2025 The Author(s); This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).
如何引用
Zhang, X., Zhang, L., Fan, L. and Liu, Z. (2025). The Establishment of 3D Polarity-Reversed Organoids From Human Endometrial Tissue as a Model for Infection-Induced Endometritis. Bio-protocol 15(12): e5349. DOI: 10.21769/BioProtoc.5349.
分类
细胞生物学 > 细胞分离和培养 > 3D细胞培养
医学 > 发炎
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link